The issue of aspartame safety has been controversial since approval by FDA, many years ago. It seems as if there are two points of views, either supporting the use of aspartame, or suggesting its dangers. Numerous research articles raised concerns regarding the adverse effects and particularly related to the metabolic components. The comments of JD Fernstrom will now be addressed in Box 1.
Box 1 Continued

Comments of JD Fernstrom
Our comments microdialysis and post-mortem tissue punch studies indicate that this magnitude of decline decreases brain 5-HT (serotonin) and catecholamine synthesis' (Palmour et al., 1998; McTavish, Cowen and Sharp, 1999; Leyton et al., 2003 Leyton et al., , 2004 ). Contrary to the authors' statement, my 1983 Life Sciences paper did not find changes in regional brain catecholamine concentrations following aspartame dosing of rats.
The sentence should have read as follows: Aspartame ingestion directly results in an increase in brain phenylalanine and tyrosine levels (Fernstrom et al., 1983) . This may lead to changes in the regional brain concentrations of catecholamines (e.g. Dopamine) (Coulombe and Sharma, 1986 ). Maher and Wurtman gave rats aspartame up to 2000 mg/kg, a huge dose. Also, their results could not be confirmed (see Coulombe and Sharma, 1986; Christian et al., 2004) .
Professor Wurtman from MIT is a renowned researcher with more than 1000 articles that include more that 50 Science and Nature articles. There is also research with much lower doses that did see changes due to aspartame. References include the following: Dow-Edwards et al. (1989) administered 500 mg/kg aspartame to pregnant guinea pigs and found that this aspartame exposure throughout gestation disrupts odor-associative learning in 15-day-old guinea pigs. Christian et al. (2004) used a dosage of 250 mg/kg per day for 4 months and the authors demonstrated that chronic aspartame consumption in rats can lead to altered T-maze performance and increased muscarinic cholinergic receptor densities in certain brain regions. Mead (2006) wrote 'Aspartame-fed females showed significant evidence of lymphomas/ leukemias and of carcinomas of the renal pelvis and ureter. The effect on the renal pelvis was much more evident when carcinomas were combined with atypical preneoplastic lesions. The researchers also observed an insignificant increase in incidence of malignant schwannomas of the peripheral nerves in males, as well as hyperplasia of the olfactory epithelium in males and females. Lesions of the kidney and olfactory epithelium are extremely rare in this strain of rats and therefore merit special attention'. Also: Mead (2007) and Soffritti et al. (2006) wrote 'The carcinogenic effects were evident at daily doses as low as 400 parts per million, equivalent to an assumed daily human intake of 20 milligrams per kilogram body weight (mg/kg). This dosage is much less than the acceptable daily intake for humans, with current limits set at 50 mg/kg in the United States and 40 mg/kg in Europe. Surveys of aspartame intake in the United States and Europe from 1984 to 1992 showed that consumers typically consumed 2-3 mg/kg daily, with small children and women of child-bearing age consuming slightly more, at 2-5 mg/kg daily'. Aspartame does not enter the blood from the gut, and thus does not get into the brain. Hence, brain glutamate receptors cannot be engaged directly by aspartame, despite the authors' assertions.
We did not say that aspartame enters from the gut. We mention that aspartame's metabolic components enter the blood via the gut. But: We referenced Fountain et al. (1988) , who mentioned the above. Also, Pan-Hou et al. (1990) suggested that 'aspartame may act directly on the NMDA glutamate recognition sites in the brain synaptic membranes'. Also: 'The safety of two flavour enhancers monosodium glutamate and aspartame has been examined extensively, and concerns have been expressed over their excitotoxic effects, i.e. their potential for destroying central neurons by excessive stimulation of postsynaptic excitatory membrane receptors, predominantly the NMDA subtype of the glutamate receptor' (Olney, 1988; Rothman and Olney, 1995) . Despite the authors' statement, my 1994 Journal of the American Dietetic Association article does not state that aspartame increases brain levels of acidic amino acids.
Here is the sentence that we referenced directly from the 1994 article (in the abstract): 'Nevertheless, the food additives monosodium glutamate and aspartame (which contains aspartate) have been reputed to raise the level of acidic amino acid in the brain (when ingested in enormous amounts), to modify brain function, and even to cause neuronal damage'. 'Several studies have shown that these excitotoxins (monosodium glutamate and aspartame), when administered to neonatal animals, produce acute neuronal degeneration in the retina and in specialized regions of the brain: the circumventricula organs that lack the blood brain barriers' (Olney, 1969a; Olney and Ho, 1970; Olney et al., 1972; Lau et al., 2006) There is no such thing as 'excitotoxic-saturated placental blood flow' caused by maternal aspartame consumption.
There is research that suggests that phenylalanine is concentrated in the foetal side of the placenta. Aspartate does not readily cross the placenta; however, the other metabolic compounds may do so. Phenylalanine: Rouse et al. (2000) performed a study on woman with PKU to determine the effects of phenylalanine on offspring. Women presented with babies that had congenital heart defects and microcephaly. These results were confirmed by Matalon et al. (2003) . Paolini et al. (2001a, b) stated 'That in human pregnancy the in vivo placental transport of amino acids that preferentially use exchange transporters (leucine and phenylalanine) is much more rapid than of amino acids that do not (glycine and proline)'.
Letters to the Editor and close our eyes to even one paper that suggests that a product may influence the health of innocent consumers and unborn babies? What if it is indeed true that the health of only one person is negatively influenced by aspartame consumption? Is it not our responsibility as researchers to prevent this? Millions of people use this product, not necessarily at abuse doses, but every day of their lives, Dr Fernstrom what ify.
Box 1 Continued Comments of JD Fernstrom
Our comments 'Previous in vivo studies have demonstrated that amino acids with the most rapid flux from mother to foetus use exchange transporters located on the foetal surface of the trophoblast that have properties similar to the sodium-independent 1 system (Jozwik et al., 1998; Paolini et al., 2001a, b) . Both branched chain amino acids and phenylalanine have been shown to use this exchange transporter' (Battaglia and Regnault, 2001 ). Sturtevant (1985) (abstract): 'Phenylalanine is concentrated on the foetal side of the placenta'. Methanol: 'Transplacental methanol toxicokinetics has been demonstrated; methanol appears to decrease uteroplacental perfusion in a concentration-dependant fashion in both rats and mice, limiting the ability of methanol to diffuse into the conceptual department' (Ward and Pollack, 1996b) . Finally, many erroneous statements have been obtained from two web sites, one cited as Mehl-Madrona, the other as Bowen and Evangelista. These seem to me to be inappropriate references, as their contents have not been subjected to peer review, and contain unsupported speculation.
The research mentioned in the web site of Mehl-Madrona is substantiated by peer-reviewed articles: Memory loss is thought to be due to aspartic acid and phenylalanine being neurotoxic without the other amino acids found in protein. These neurotoxic agents may go past the BBB and deteriorate the neurons of the brain (Mehl-Madrona, 2005) . Two references to confirm this statement: Maher and Wurtman (1987) (abstract): 'If mice are given aspartame in doses that elevate plasma phenylalanine levels more than those of tyrosine (which probably occurs after any aspartame dose in humans), the frequency of seizures following the administration of an epileptogenic drug, pentylenetetrazole, is enhanced. This effect is simulated by equimolar phenylalanine and blocked by concurrent administration of valine, which blocks phenylalanine's entry into the brain'. Also, Lau et al. (2006) mentioned that aspartame could produce acute neuronal degeneration in the retina and in specialized regions of the brain. In addition, Mehl-Madrona (2005) states that when the temperature of aspartame exceeds 86 degrees F, the wood alcohol in aspartame converts to formaldehyde and then to formic acid, which in turn causes metabolic acidosis. Reference to confirm this statement: Lim (2007) : metabolic acidosis can occur as a result of either the accumulation of endogenous acids that consume bicarbonate (high anion gap metabolic acidosis) or the loss of bicarbonate from the gastrointestinal tract or the kidney (hyperchloremic or normal anion gap metabolic acidosis). The cause of high anion gap metabolic acidosis includes lactic acidosis, ketoacidosis, renal failure and intoxication with ethylene glycol, methanol, salicyclate and less commonly with pyroglutamic acid, propylene glycole or djenkol bean. In addition, it is thought that the methanol in the aspartame converts to formaldehyde in the retina of the eye, causing blindness (Mehl-Madrona, 2005) . Reference to confirm this statement: Hayasaka et al. (2001) reported that rabbits 1 month after receiving 0.1% formaldehyde showed retinal vessel dilation, and the rabbits that received 1% formaldehyde showed mild posterior subcapsular cataract and retinal vessel dilatation and haemorrhages. These same animals, 1 month after treatment developed mild posterior subcapsular cataract and retinal lesions. Also, histologically disorganized retina and optic nerve were seen in eyes that received 0.1 or 1% formaldehyde. Mehl-Madrona (2005) also cited research findings implicating aspartame consumption at the time of conception to consequent birth defects, because the phenylalanine concentrates in the placenta, causing mental retardation. Peer-reviewed articles that confirm this statement are Rouse et al. (2000) ; Matalon et al. (2003); and Paolini et al. (2001a, b) . Ingestion of aspartame results in a craving for carbohydrates, which will eventually result in weight gain, especially because the formaldehyde stores in the fat cells, particularly in the hips and thighs; therefore, aspartame is thought to make diabetic control especially problematic (Mehl-Madrona, 2005) . This is a statement that was made by a Dr Dr HJ Roberts, diabetic specialist, in the Congressional record (Congressional Record SID835: 131 (August 1, l985)). Bowen and Evangelista: their 2002 web site makes use of many peer-reviewed articles and it is noteworthy that AM Evangelista is a former FDA investigator. The following comments relate to the review by Humphries et al. (2008) . The premise of the review, that the highintensity sweetener aspartame is neurotoxic, ignores a very large scientific literature to the contrary, recently comprehensively summarized (Butchko et al., 2002; Magnuson et al., 2007) .
Aspartame effects on the brain
The key point about aspartame is that very little is consumed. Because it is 180 times sweeter than sugar, relatively little shows up in products. For example, a 355 ml can of diet soda contains 180 mg of aspartame, which for a 70 kg human is a 2.5 mg kg À1 dose (1.25 mg kg À1 phenylalanine). After its introduction, its use was monitored for years, revealing that average daily dosing is barely 5 mg kg À1 day
À1
(2.5 mg kg À1 day À1 phenylalanine), not much. As a comparison, the amount of phenylalanine in a quarter-pound hamburger is about 1000 mg, or 14 mg kg À1
